A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Biliary cancer
- Focus Adverse reactions
- 14 Feb 2018 Status changed from suspended to withdrawn prior to enrolment.
- 06 Jul 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 06 Jul 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrials.gov.